BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
BECTON DICKINSON & CO
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$190.74−1.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $52.48B
- P/E (TTM)
- 57.6
- Dividend yield
- 2.18%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
278M of 272M shares
Institutional holders
1,434
139 new, 151 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
0 buys · 22 sales
Net sold $2.78M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 22,774,866 | 7.90% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 21,397,756 | 7.51% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 15,388,359 | 5.40% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 15,014,710 | 5.40% | 13G (passive) | Jun 30, 2026 |
| First Eagle Investment Management, LLC | 14,138,027 | 5.10% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| First Eagle Investment Management, LLC | 27,630,670 | 10.14% | $4.18B | +15,702,559 | 3.47% |
| BlackRock, Inc. | 24,592,166 | 9.03% | $3.72B | −1,561,245 | 0.06% |
| Vanguard Capital Management LLC | 17,987,834 | 6.60% | $2.72B | −502,776 | 0.06% |
| State Street Corp | 15,000,064 | 5.51% | $2.27B | +1,177,256 | 0.07% |
| Vanguard Portfolio Management LLC | 14,974,136 | 5.50% | $2.27B | −343,106 | 0.10% |
| Invesco Ltd. | 8,898,488 | 3.27% | $1.35B | −1,275,839 | 0.11% |
| Massachusetts Financial Services Co /Ma/ | 8,650,967 | 3.18% | $2.48B | −450,487 | 0.79% |
| Geode Capital Management, LLC | 8,141,586 | 2.99% | $1.23B | +1,034,323 | 0.07% |
| Franklin Resources Inc | 7,011,592 | 2.57% | $1.06B | +1,648,627 | 0.23% |
| Wellington Management Group Llp | 6,357,986 | 2.33% | $962.15M | −257,244 | 0.17% |
| Greenhaven Associates Inc | 5,681,708 | 2.09% | $859.81M | New | 9.93% |
| Norges Bank | 4,169,523 | 1.53% | $630.97M | New | 0.06% |
| Price T Rowe Associates Inc /Md/ | 3,907,969 | 1.43% | $591.39K | −511,255 | 0.06% |
| T. Rowe Price Investment Management, Inc. | 3,722,952 | 1.37% | $563.40K | −5,962,319 | 0.37% |
| American Century Companies Inc | 3,676,534 | 1.35% | $556.37M | +270,617 | 0.25% |
| Charles Schwab Investment Management Inc | 3,398,203 | 1.25% | $515.29M | +74,076 | 0.07% |
| Morgan Stanley | 3,319,590 | 1.22% | $502.35M | −701,082 | 0.03% |
| Clearbridge Investments, LLC | 3,232,819 | 1.19% | $489.22M | −907,223 | 0.40% |
| Bank Of America Corp /De/ | 3,138,786 | 1.15% | $474.99M | +470,340 | 0.03% |
| JPMorgan Chase & Co | 2,835,692 | 1.04% | $440.07M | −734,632 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,434 | 278M | 100.0% | 139 / 545 | 547 / 151 | 46M | 30M |
| Q1 2026 | 1,473 | 263M | 96.5% | 133 / 589 | 521 / 191 | 59M | 37M |
| Q4 2025 | 1,549 | 278M | 100.0% | 219 / 455 | 675 / 120 | 38M | 22M |
| Q3 2025 | 1,483 | 264M | 97.0% | 142 / 583 | 556 / 161 | 34M | 29M |
| Q2 2025 | 1,520 | 260M | 95.4% | 164 / 554 | 598 / 238 | 39M | 39M |
| Q1 2025 | 1,611 | 260M | 95.4% | 136 / 608 | 620 / 131 | 22M | 20M |
| Q4 2024 | 1,627 | 260M | 95.5% | 204 / 547 | 644 / 130 | 22M | 23M |
| Q3 2024 | 1,578 | 262M | 96.1% | 127 / 567 | 627 / 117 | 41M | 16M |
| Q2 2024 | 1,586 | 259M | 95.0% | 113 / 623 | 591 / 107 | 19M | 36M |
| Q1 2024 | 1,602 | 279M | 100.0% | 144 / 595 | 617 / 115 | 29M | 18M |
| Q4 2023 | 1,594 | 268M | 98.5% | 190 / 499 | 657 / 124 | 31M | 19M |
| Q3 2023 | 1,554 | 257M | 94.4% | 109 / 545 | 589 / 114 | 15M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| First Eagle Global Fund | 9,151,995 | 3.36% | $1.52B | 1.99% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,747,261 | 3.21% | $1.32B | 0.06% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 7,136,026 | 2.62% | $1.08B | 0.06% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 5,970,167 | 2.19% | $903.47M | 0.40% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 3,789,927 | 1.39% | $573.53M | 0.06% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 3,643,849 | 1.34% | $536.08M | 0.06% | May 31, 2026 |
| Putnam Large Cap Value Fund | 3,064,012 | 1.12% | $507.46M | 0.92% | Jul 31, 2026 |
| Vanguard Equity Income Fund | 2,901,351 | 1.07% | $439.06M | 0.67% | Jun 30, 2026 |
| Vanguard Value Index Fund | 2,620,600 | 0.96% | $396.58M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,012,183 | 0.74% | $304.50M | 0.43% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,946,609 | 0.71% | $294.58M | 0.73% | Jun 30, 2026 |
| Vanguard Mid-Cap Value Index Fund | 1,769,753 | 0.65% | $267.82M | 0.72% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 1,558,991 | 0.57% | $258.20M | 0.20% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Dividend ETF | 1,515,922 | 0.56% | $229.40M | 1.07% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 1,496,005 | 0.55% | $226.39M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas E. Polen Jr | Chairman, CEO and President, Director | 153,441 | 0.06% | Aug 14, 2026 |
| Michael Feld | EVP, Chief Revenue Officer | 19,644 | 0.01% | Sep 29, 2026 |
| Vitor Roque | EVP & Chief Financial Officer | 8,041 | 0.00% | Sep 3, 2026 |
| Roland Goette | EVP and President, EMEA | 16,635 | 0.01% | Aug 12, 2026 |
| Bilal Muhsin | EVP & President Connected Care | 41,359 | 0.02% | Jul 6, 2026 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 13,172 | 0.00% | Jun 25, 2026 |
| Manish Sinha | EVP and Chief People Officer | 8,806 | 0.00% | Jun 22, 2026 |
| Peter Menziuso | EVP and President, BDI | 0 | – | Jun 2, 2026 |
| Shana Carol Neal | EVP and Chief People Officer | 23,966 | 0.01% | Apr 6, 2026 |
| Lanesha Minnix | EVP and General Counsel | 0 | – | Mar 17, 2026 |
| Pamela L. Spikner | SVP Controller & CAO | 3,323 | 0.00% | Mar 4, 2026 |
| Massimiliano Urbini | EVP & Chief ISC Officer | 4,133 | 0.00% | Feb 6, 2026 |
| David Shan | EVP and Chief ISC Officer | 8,926 | 0.00% | Jan 6, 2026 |
| Christopher DelOrefice | EVP & Chief Financial Officer | 27,227 | 0.01% | Dec 1, 2025 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 5,055 | 0.00% | Dec 1, 2025 |
| Richard Byrd | EVP & President Interventional | 13,183 | 0.00% | Dec 1, 2025 |
| Michelle Quinn | EVP and General Counsel | 7,303 | 0.00% | Dec 3, 2024 |
| Antoine C. Ezell | EVP, President Americas & CMO | 13,327 | 0.00% | Nov 29, 2024 |
| Carrie L. Byington | Director | 5,018 | 0.00% | Aug 6, 2026 |
| Robert Luther Huffines | Director | 1,279 | 0.00% | Aug 6, 2026 |
| Bertram L. Scott | Director | 36,763 | 0.01% | Feb 18, 2026 |
| Christopher Ian Montague Jones | Director | 24,304 | 0.01% | Feb 5, 2026 |
| Timothy M. Ring | Director | 61,445 | 0.02% | Jan 29, 2026 |
| Joanne Waldstreicher | Director | 3,391 | 0.00% | Jan 29, 2026 |
| William M. Brown | Director | 4,663 | 0.00% | Jan 29, 2026 |
| R. Andrew Eckert | Director | 10,423 | 0.00% | Jan 29, 2026 |
| Gregory Hayes | Director | 7,159 | 0.00% | Jan 29, 2026 |
| Jacqueline Wright | Director | 1,279 | 0.00% | Jan 29, 2026 |
| Jeffrey William Henderson | Director | 9,158 | 0.00% | Jan 29, 2026 |
| Claire Fraser | Director | 22,226 | 0.01% | Sep 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Feld EVP, Chief Revenue Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −76 | $183.70 | $13.96K | 19,644 |
| Vitor Roque EVP & Chief Financial Officer | Sep 2, 2026 | Tax withholding | −190 | – | – | 8,041 |
| Michael Feld EVP, Chief Revenue Officer | Aug 26, 2026 | Sale(10b5-1 plan) | −165 | $188.49 | $31.10K | 19,720 |
| Michael Feld EVP, Chief Revenue Officer | Aug 20, 2026 | Tax withholding | −1,049 | – | – | 19,885 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Option exercise | +43,278 | $167.25 | $7.24M | 153,441 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Sale(10b5-1 plan) | −4,152 | $185.00 | $768.12K | 110,163 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Aug 13, 2026 | Returned to company | −39,126 | $185.00 | $7.24M | 114,315 |
| Roland Goette EVP and President, EMEA | Aug 11, 2026 | Sale | −2,438 | $180.84 | $440.89K | 14,856 |
| Michael Feld EVP, Chief Revenue Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −75 | $157.13 | $11.78K | 20,934 |
| Bilal Muhsin EVP & President Connected Care | Jul 2, 2026 | Tax withholding | −1,935 | – | – | 41,359 |
| Bilal Muhsin EVP & President Connected Care | Jul 1, 2026 | Award | +14,342 | – | – | 43,294 |
| Michael Feld EVP, Chief Revenue Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −75 | $152.80 | $11.46K | 21,009 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jun 24, 2026 | Sale(10b5-1 plan) | −1,100 | $145.66 | $160.23K | 13,172 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jun 10, 2026 | Sale(10b5-1 plan) | −1,100 | $151.48 | $166.63K | 14,272 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Returned to company | −17,445 | $146.15 | $2.55M | 108,235 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −2,764 | $146.35 | $404.51K | 110,163 |
| Thomas E. Polen Jr Chairman, CEO and President, Director | Jun 1, 2026 | Option exercise | +20,209 | $126.16 | $2.55M | 125,680 |
| Peter Menziuso EVP and President, BDI | Jun 1, 2026 | Award | +14,258 | – | – | 14,258 |
| Michael Feld EVP, Chief Revenue Officer | May 26, 2026 | Sale(10b5-1 plan) | −75 | $147.35 | $11.05K | 21,084 |
| Vitor Roque EVP & Chief Financial Officer | May 7, 2026 | Award | +1,721 | – | – | 8,231 |
| Michael Feld EVP, Chief Revenue Officer | Apr 27, 2026 | Sale(10b5-1 plan) | −74 | $151.94 | $11.24K | 21,159 |
| Shana Carol Neal EVP and Chief People Officer | Apr 6, 2026 | Tax withholding | −1,146 | – | – | 23,966 |
| Michael Feld EVP, Chief Revenue Officer | Mar 26, 2026 | Sale(10b5-1 plan) | −75 | $156.83 | $11.76K | 21,233 |
| Lanesha Minnix EVP and General Counsel | Mar 16, 2026 | Award | +7,492 | – | – | 7,492 |
| Pamela L. Spikner SVP Controller & CAO | Mar 2, 2026 | Award | +931 | – | – | 3,323 |
| Vitor Roque Interim CFO | Mar 2, 2026 | Award | +931 | – | – | 6,510 |
| Michael Feld EVP, Chief Revenue Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −75 | $181.84 | $13.64K | 21,308 |
| Bertram L. Scott Director | Feb 18, 2026 | Sale | −953 | $182.61 | $174.03K | 36,763 |
| Joanne Waldstreicher Director | Jan 27, 2026 | Award | +1,098 | – | – | 3,391 |
| Bertram L. Scott Director | Jan 27, 2026 | Award | +1,098 | – | – | 37,716 |
| Jacqueline Wright Director | Jan 27, 2026 | Award | +1,098 | – | – | 1,279 |
| William M. Brown Director | Jan 27, 2026 | Award | +1,098 | – | – | 4,663 |
| Robert Luther Huffines Director | Jan 27, 2026 | Award | +1,098 | – | – | 1,279 |
| Carrie L. Byington Director | Jan 27, 2026 | Award | +1,098 | – | – | 5,018 |
| R. Andrew Eckert Director | Jan 27, 2026 | Award | +1,098 | – | – | 10,423 |
| Timothy M. Ring Director | Jan 27, 2026 | Award | +1,098 | – | – | 59,160 |
| Jeffrey William Henderson Director | Jan 27, 2026 | Award | +1,098 | – | – | 9,143 |
| Christopher Ian Montague Jones Director | Jan 27, 2026 | Award | +1,098 | – | – | 24,304 |
| Gregory Hayes Director | Jan 27, 2026 | Award | +1,098 | – | – | 7,159 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Jan 26, 2026 | Sale(10b5-1 plan) | −75 | $202.73 | $15.20K | 16,431 |
| Pamela L. Spikner SVP Controller & CAO | Jan 21, 2026 | Tax withholding | −84 | – | – | 1,832 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Returned to company | −2,454 | $209.00 | $512.89K | 13,705 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Option exercise | +3,054 | $167.91 | $512.80K | 16,159 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Sale(10b5-1 plan) | −600 | $209.00 | $125.40K | 13,105 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Sale(10b5-1 plan) | −1,010 | $206.54 | $208.61K | 12,095 |
| David Shan EVP and Chief ISC Officer | Jan 3, 2026 | Tax withholding | −44 | – | – | 8,926 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Dec 26, 2025 | Sale(10b5-1 plan) | −74 | $196.08 | $14.51K | 16,506 |
| Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Dec 17, 2025 | Sale(10b5-1 plan) | −629 | $196.03 | $123.30K | 13,105 |
| Jacqueline Wright Director | Dec 1, 2025 | Award | +180 | – | – | 180 |
| Michael Feld EVP, CRO & Pres. Life Sciences | Dec 1, 2025 | Sale(10b5-1 plan) | −75 | $193.36 | $14.50K | 16,580 |
| Robert Luther Huffines Director | Dec 1, 2025 | Award | +180 | – | – | 180 |
| Pamela L. Spikner SVPController & Chief Acct Off | Nov 26, 2025 | Award | +1,234 | – | – | 1,916 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Award | +6,447 | – | – | 13,183 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Award | +2,385 | – | – | 15,568 |
| Richard Byrd EVP & President Interventional | Nov 26, 2025 | Tax withholding | −1,719 | – | – | 13,849 |
| Roland Goette EVP and President, EMEA | Nov 26, 2025 | Award | +1,906 | – | – | 16,123 |
| Roland Goette EVP and President, EMEA | Nov 26, 2025 | Tax withholding | −138 | – | – | 17,222 |
| Roland Goette EVP and President, EMEA | Nov 26, 2025 | Award | +1,237 | – | – | 17,360 |
| Bilal Muhsin EVP & President Connected Care | Nov 26, 2025 | Award | +9,530 | – | – | 21,751 |
| David Shan EVP and Chief ISC Officer | Nov 26, 2025 | Tax withholding | −134 | – | – | 8,970 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Feld Michael Officer | Sep 28, 2026 | 76 | $13.97K | Sep 28, 2026 | Restricted Stock Units |
| Feld Michael Officer | Aug 26, 2026 | 165 | $31.31K | Aug 26, 2026 | Restricted Stock Units |
| Byrd Richard Former Officer | Aug 20, 2026 | 1,330 | $249.99K | Aug 20, 2026 | Exercise of Options Under a Registered Plan |
| Polen Thomas Director, Officer | Aug 13, 2026 | 4,152 | $762.22K | Aug 13, 2026 | Exercise of Stock Options |
| Goette Roland Officer | Aug 11, 2026 | 2,438 | $440.88K | Aug 11, 2026 | GSIP |
| Neal Shana Officer | Aug 3, 2026 | 1,500 | $248.43K | Aug 3, 2026 | Restricted Stock Units |
| Feld Michael Officer | Jul 27, 2026 | 75 | $11.73K | Jul 27, 2026 | Restricted Stock Units |
| Feld Michael Officer | Jun 26, 2026 | 75 | $11.35K | Jun 26, 2026 | Restricted Stock Units |
| Garrison Michael Officer | Jun 24, 2026 | 1,100 | $158.31K | Jun 24, 2026 | Restricted Stock Units |
| Garrison Michael Officer | Jun 10, 2026 | 1,100 | $167.24K | Jun 10, 2026 | Restricted Stock Units |
| Polen Thomas Officer | Jun 1, 2026 | 2,764 | $406.64K | Jun 1, 2026 | Exercise of Stock Options |
| Feld Michael Officer | May 26, 2026 | 75 | $11.07K | May 26, 2026 | Restricted Stock Units |
| Feld Michael Officer | Apr 27, 2026 | 74 | $11.26K | Apr 27, 2026 | Restricted Stock Units |
| Feld Michael Officer | Mar 26, 2026 | 75 | $11.87K | Mar 26, 2026 | Restricted Stock Units |
| Feld Michael Officer | Feb 26, 2026 | 75 | $13.57K | Feb 26, 2026 | Restricted Stock Units |